Methods of using zonisamide as an adjunctive therapy for partial seizures
are disclosed. In particular, the methods enhance the safety of patients
taking pharmaceutical formulations of zonisamide by providing information
that increases the awareness of neuroleptic malignant syndrome (NMS) as a
possible side effect; wherein the patients and/or prescribing physicians
and other medical care providers are advised to monitor for NMS and
employ methods that will improve the therapeutic outcome in the few
patients who experience NMS associated with zonisamide therapy.
